Fesoterodine

Generic Name: Fesoterodine

Brand Names: Toviaz

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₃₇NO_₃

CAS Number: 286930-02-7

Unique Ingredient Identifier: 621G617227

Background: Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.

Indication: 适用于治疗急迫性尿失禁和膀胱过度活动综合征患者的尿频、尿急、尿失禁或所有这些症状组合。

Associated Conditions: Neurogenic Detrusor Overactivity, Overactive Bladder Syndrome (OABS)

Associated Therapies: -

Clinical Trials

Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive Bladder

Phase 4

Completed

Conditions: Overactive Bladder

Interventions: Drug: Imidafenacin
Drug: Fesoterodine

First Posted Date: 2012-04-16

Last Posted Date: 2012-04-16

Lead Sponsor: LG Life Sciences

Target Recruit Count: 207

Registration Number: NCT01578304

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Comparative Urine Proteomic Studies of Overactive Bladder in Humans

Not Applicable

Completed

Conditions: Overactive Bladder

Interventions: Drug: fesoterodine

First Posted Date: 2011-06-07

Last Posted Date: 2015-02-27

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 21

Registration Number: NCT01367886

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States

This Is A Study Of Bioavailability And Food Effect For Fesoterodine.

Phase 1

Completed

Conditions: Overactive Bladder (OAB) With Symptoms of Frequency, Urgency, and Urgency

Interventions: Drug: fesoterodine

First Posted Date: 2011-01-31

Last Posted Date: 2012-01-26

Lead Sponsor: Pfizer

Target Recruit Count: 20

Registration Number: NCT01286454

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

Post Marketing Surveillance Of Fesoterodine In Filipino Patients With Over Active Bladder

Completed

Conditions: Over Active Bladder

Interventions: Drug: Fesoterodine

First Posted Date: 2010-12-15

Last Posted Date: 2014-09-11

Lead Sponsor: Pfizer

Target Recruit Count: 508

Registration Number: NCT01260311

Locations: 🇵🇭
Mary Johnston Hospital, Inc., Tondo, Manila, Philippines
🇵🇭
The Medical City, Pasig City, Metro Manila, Philippines
🇵🇭
St. Luke's Medical Center, Quezon City, Metro Manila, Philippines

and more 21 locations

Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients With Overactive Bladder

Phase 4

Completed

Conditions: Urinary Bladder, Overactive

Interventions: Drug: Fesoterodine

First Posted Date: 2010-01-22

Last Posted Date: 2013-05-15

Lead Sponsor: Pfizer

Target Recruit Count: 31

Registration Number: NCT01054222

Locations: 🇵🇹
Hospital Ordem do Carmo, Porto, Portugal
🇵🇹
Hospital de São João, Porto, Portugal
🇵🇹
Centro de Avaliação Geriátrica, Lisboa, Portugal

Evaluation Of The Ability Of Fesoterodine To Increase Urethral Pressure In Stress Urinary Incontinence Patients

Phase 2

Completed

Conditions: Stress Urinary Incontinence

Interventions: Drug: Fesoterodine

First Posted Date: 2010-01-05

Last Posted Date: 2011-07-22

Lead Sponsor: Pfizer

Target Recruit Count: 22

Registration Number: NCT01042236

Locations: 🇩🇰
Glostrup Hospital, Glostrup, Denmark

This Is An Open-Label Study To Evaluate Fesoterodine Plus "Your Way" Patient Support Plan In Patients With Symptoms Of Overactive Bladder

Completed

Conditions: Overactive Bladder

Interventions: Drug: Fesoterodine
Behavioral: Your Way

First Posted Date: 2009-07-22

Last Posted Date: 2018-12-04

Lead Sponsor: Pfizer

Target Recruit Count: 774

Registration Number: NCT00943735

A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder

Phase 4

Completed

Conditions: Overactive Bladder

Interventions: Drug: Fesoterodine
Drug: Placebo

First Posted Date: 2009-06-25

Last Posted Date: 2013-01-17

Lead Sponsor: Pfizer

Target Recruit Count: 566

Registration Number: NCT00928070

Locations: 🇺🇸
Pfizer Investigational Site, Spokane, Washington, United States

A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency

Phase 4

Completed

Conditions: Overactive Bladder

Interventions: Drug: Placebo
Drug: Fesoterodine

First Posted Date: 2009-06-03

Last Posted Date: 2018-12-04

Lead Sponsor: Pfizer

Target Recruit Count: 963

Registration Number: NCT00911937

Locations: 🇺🇸
Pfizer Investigational Site, Menomonee Falls, Wisconsin, United States

The Effect Of Fluconazole On Pharmacokinetics Of Fesoterodine In Healthy Subjects

Phase 1

Completed

Conditions: Overactive Bladder With Symptoms of Frequency, Urgency, and Urge Urinary Incontinence

Interventions: Drug: fesoterodine plus fluconazole
Drug: Fesoterodine

First Posted Date: 2009-06-01

Last Posted Date: 2011-06-01

Lead Sponsor: Pfizer

Target Recruit Count: 28

Registration Number: NCT00911235

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy